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Recently it has become possible to investigate expression of all human genes with microarray technique. The authors provide argu-
ments to consider peripheral white blood cells and in particular lymphocytes as a model for the investigation of pathophysiology of
asthma, RA, and SLE diseases in which inﬂammation is a major component. Lymphocytes are an alternative to tissue biopsies that
are most often diﬃcult to collect systematically. Lymphocytes express more than 75% of the human genome, and, being an impor-
tant part of the immune system, they play a central role in the pathogenesis of asthma, RA, and SLE. Here we review alterations of
gene expression in lymphocytes and methodological aspects of the microarray technique in these diseases. Lymphocytic genes may
become activated because of a general nonspeciﬁc versus disease-speciﬁc mechanism. The authors suppose that in these diseases
microarray proﬁles of gene expression in lymphocytes can be disease speciﬁc, rather than inﬂammation speciﬁc. Some potentials
and pitfalls of the array technologies are discussed. Optimal clinical designs aimed to identify disease-speciﬁc genes are proposed.
Lymphocytes can be explored for research, diagnostic, and possible treatment purposes in these diseases, but their precise value
should be clariﬁed in future investigation.
INTRODUCTION
During the last 5 years, microarrays have been devel-
oped for large-scale clinical research and routine to iden-
tify genes involved in disease states. At present, microar-
rays comprising the whole human genome (all 30000
genes) have become commercially available and their po-
tential to identify abnormal gene activity in disease is now
well recognized. The microarray approach is particularly
suited to identify the activity of genes that are diﬀerently
expressed during a disease state and that may become
normalized following recovery of the patient. So, perhaps
more than with the conventional gene-identiﬁcation ap-
proach, the success of the microarrays technique depends
heavily on proper clinical designs. The most promising
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geneexpressionproﬁleshavebeenderivedfromcancerre-
search [1, 2, 3, 4] using tumor tissue and peripheral blood
mononuclear cells (PBMCs). In internal diseases such as
pulmonary diseases [5], including asthma [6], autoim-
mune disorders, for example, rheumatoid arthritis (RA)
[7], systemic lupus erythematosus (SLE) [8], cardiovas-
cular diseases [9], psychiatric disorders [10, 11], and oth-
ers as nicely reviewed [12] have used mainly conventional
mRNA-assay techniques.
PBMCs—and in particular lymphocytes—are partic-
ularly convenient for medical research and diagnostic ap-
plications, because they can easily and repeatedly be col-
lected in suﬃcient quantities in the course of the dis-
ease. The involvement of T cells and B cells in the patho-
genesis of asthma is well recognized; particularly that of
Th2 cells both in atopic allergic asthma and nonatopic
and occupational asthma [6, 13]. In SLE immune ab-
normalities in a wide variety of cell populations to in-
clude B and T lymphocytes, monocytes, and natural killer
(NK) cells have been noticed [8]. Defects of phenotypic
and functional T cells were found in RA, including ab-
normal clonal expansions and suppressed proliferative re-
sponses, which suggest a defect in T-cell diﬀerentiation
[14]. Excessive Th1-type cytokines have been associated
withtissuedestructionasfoundinautoimmunediseaseas
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implicated in atopy and allergic asthma. Altered function
of lymphocytes in diseases is a result of abnormal expres-
sion of genes for numerous cytokines, receptor compo-
nents, signal transduction pathways, and modulators of
transcription and translation. In addition, polymorphism
ofthegenesaﬀectstheirfunctionalproperties.Despite in-
tensive studies, the pathophysiological and pathogenetic
mechanisms behind these diseases are still poorly under-
stood.
PBMCs comprise a very heterogeneous population
and the question may arise whether meaningful informa-
tion on gene expression on particular processes can in-
deed be deduced from these cells. Could it be that—for
instance—in the diseased state the relative composition
of the population just changes without alterations in the
gene-expression of the individual cell per se? In that case
thechangesseenmaymerelyreﬂectchangesinpopulation
of cells. But even if this is the case, it should be realized
that such changes do not occur without changes in intra-
cellular transduction and gene expression. Activation of
sympathetic associated beta-adrenergic receptors causes
the release of lymphocytes from the spleen. Changes in
cortisol suppress proliferation of certain subpopulations
of lymphocytes. Anyway, such receptor-mediated eﬀects
are concomitant with altered gene expression, which is
considered indicative of the disease state.
Interest of gene expression of PBMCs concerns with
identifying both pathogenetic and pathophysiological
processes. Pathogenetic processes are primarily associated
with the cause of a disease, so microarrays may lead to the
identiﬁcation of abnormal genes and gene activities that
may not be only limited to PBMCs, but may occur in cells
of pathological tissue as well, or—alternatively—that the
immunereactionbyitselfisabnormal.Incontrast,patho-
physiological changes in lymphocytic gene expression are
considered as an essentially normal reaction of the im-
mune system to an abnormal, that is, pathological, stimu-
lus. So, at least theoretically, pathophysiological gene pro-
ﬁles may be shared in a variety of diseases, whereas patho-
genetic gene expression is expected to be disease speciﬁc.
To discuss this issue in more detail, we will compare lym-
phocytic gene expression proﬁles in asthma, SLE, and RA.
Becauseofpresumablydiﬀerentpathogenesisofthesedis-
eases, common gene-expression proﬁles point to a gen-
eral response of the immune system, whereas diﬀeren-
tial proﬁles are likely to be related to disease-speciﬁc pro-
cesses.
The latter is important for diagnostic applications, for
researchpurposes lessstringentcriteria mayalsobe,anda
variety of strategies have been proposed, so that the focus
may be on a limited number or proﬁles of genes related to
a particular gene. Accordingly, insight in gene activities in
the diseased state is obtained, but the chance is relatively
small to identify novel pathogenetic or diagnostic genes.
Often, the so-called supervised or unsupervised analyses
are applied. In the supervised approach all the expressed
genesarecorrelatedwiththatoftheexpressionofaknown
aberrant gene, so clusters of genes involved in a particu-
lar disease are identiﬁed. In the unsupervised approach
clusters of gene expression the structure (clustering) of
genes is determined, without a priori assumptions about
gene expression. Both strategies have recently been ap-
plied in acute myeloid leukemia [3, 4].
In this review we consider the potential of the mi-
croarray gene expression in lymphocytes as a proper and
convenient approach to investigate in detail pathophysi-
ological processes at the molecular level. We review the
molecular mechanisms and gene-expression patterns in-




Allergic asthma is a chronic pulmonary disease as-
sociated with bronchoconstriction and inﬂammation, in
which Th2 cells play a central role. It is well known that
allergen-speciﬁc IgE synthesis is T-cell dependent on cog-
nate activation of B lymphocytes and Th2-derived cy-
tokines, such as IL (interleukin)-4 and IL-13 [15]. T lym-
phocytes of the T-helper-2 subtype, producing IL-4, IL-5
and IL-13, have been shown to be prominent in airways
of the asthmatic patients [13, 16]. These cytokines play
pivotal roles in asthmatic disorder, since IL-4 induces IgE
production by B lymphocytes and IL-5 is the main fac-
torregulatingeosinophilia.ElevatedpercentagesofCD4T
cells expressing mRNA encoding IL-4 and IL-5, and CD8
T lymphocytes expressing IL-5, were found in asthmatics
as compared with the controls [17]. IL-13 is responsible
for inducing most of the phenotypic features of allergic
asthma (ie, airway responsiveness, mucus metaplasia, and
eosinophilic inﬂammation). The cellular targets of IL-13
responsible for each of the phenotypic features of asthma
and the speciﬁc genes whose expression is regulated in
these target cells remain, however, unknown. Since the
main mode of action of IL-13 is regulating gene expres-
sion of airway tissue cells, these questions seem ideally
suited to expression array experiments [18]. Moreover,
it has recently been hypothesized that IL-13 may partic-
ipate in the pathogenesis of asthma by activating a set of
“proasthmatic” genes in airway smooth muscle cells [19].
These investigators further conﬁrm the hypothesis that
gene modulation by IL-13 in airway smooth cells is essen-
tialinthedevelopmentofallergicasthma[19].BothIL-13
andIL-4arecapableofinducingisotypeclassswitchingof
Bc e l lt op r o d u c eI g Ea f t e ra l l e r g e ne x p o s u r e[ 20].
Many more cytokines with potential relevance to
asthma have been described. So, IL-25 acts in Th2 dif-
ferentiation; IL-9, IL-11, IL-13, IL-16, and IL-17 have
been linked to asthma; and IL-12, IL-18, IL-23, IL-27
are involved in Th1 development and IFN-γ production,
which might be deﬁcient in patients with asthma [13].
In addition, IL-12 and IL-18 have the potential to re-
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sensitization [21]. Data of Kodama et al point to a role for
IL-18 in allergic inﬂammation in which IL-18 limits the
development of the local inﬂammatory response to
antigen[22].Ithasbeenreportedthatatopicasthmaisas-
sociated with a downregulation of IL-12 mRNA and also
that IL-12 suppresses the expression of Th2 cytokines and
their associated responses, including eosinophilia, serum
IgE, and mucosal mastocytosis [21]. It has been shown
that IL-3 and GM-CSF also may inﬂuence the inﬂam-
matory process in asthma through their regulatory role
on eosinophil survival, diﬀerentiation, and eﬀector func-
tion [23]. Furthermore Ferreira showed that after allergic
challenge in atopic patients IL-4, IL-5, and IL-13, as well
as the pro-inﬂammatory cytokines GM-CSF, TNF-α,a n d
IL-6 are consistently increased when compared with the
respective control value [24]. IL-10 modulates IgE pro-
duction and induces apoptosis of eosinophils [25]. IL-8,
TNF-α,andleukotrieneB4canbeusedasmarkersofneu-
trophilic inﬂammation and to evaluatethe response to in-
haled steroid therapy in asthma patients [26].
The transcription factors T-bet and GATA3 may af-
fect airway immunopathology in asthma [27]. T-bet in-
duces an IFN-γ producing Th1 phenotype, and also re-
presses IL-4 and IL-5 production from diﬀerentiated Th2
cells [28]. Finotto et al [29] provided the evidence for de-
creased number of CD4+ T cells expressing T-bet in the
airway of human asthma patients relative to control sub-
jects. Moreover, they showed deletion of the T-bet gene
in mice resulted in airway eosinophilia, Th2 cytokine pro-
duction, airway hyperresponsiveness, and changes of air-
way remodeling in the absence of allergen sensitization
and inhaled allergenchallenge. GATA3 could repress IFN-
γ production, induces IL-4 and IL-5 [30] ,a n di sa ni m -
portant controller of the IL-5 gene locus [31]. T cells
from asthmatic patients expressed 5 times the level of
GATA3; so increased expression of GATA3 may underlie
augmented Th2-like cytokines in this disease. The tran-
scription factors c-Maf, NIP45, and JunB that increase
IL-4 activation appear to be expressed solely in Th2-cells
and not Th1 cells [32]. Gene deletion or overexpression
of these factors correspondingly aﬀects IL-4 production
[32]. Other transcription factors might be crucially in-
volved in gene expression of IL-5 such as NFAT, AP-1, IL-
4, IL-13, and the signal transducer and activator of tran-
scription (STAT6) [33, 34].
Various G-protein-coupled receptors are expressed on
lymphocytes. Muscarinic receptor subtypes (M1–M5) are
involved in the control of airway function. Dysfunction
of these receptors contributes to the development of air-
way hyperresponsiveness and bronchomotor responses
associated with asthma [35]. Human lymphocytes ex-
press M2–M5 receptors and corresponding mRNA [36,
37]. Ricci et al [38] reported that lymphocytic M2 and
lesser amount of M5 receptor subtypes are increased
in bronchial asthma and that these changes are related
to bronchial hyperresponsiveness. They suggest that pe-
ripheral blood cholinergic receptors reﬂect the status of
cholinergic dysfunction and involvement of lymphocyte
cholinergic system in allergic inﬂammation.
A reduced β-adrenergic responsiveness plays an im-
portantroleintheincreasedairwayreactivityofasthmatic
patients. This hypothesis has been supported showing a
reduced β-adrenergic responsiveness in lymphocytes of
asthmatic patients, predominantly during the occurrence
of active and severe symptoms [39]. The results of Moto-
jima et al [40] suggest that beta-blockade and bronchial
hypersensitivity in asthmatic patients may in part be due
to a decreased number of β-adrenoreceptors.
An increasing body of evidence shows that nerve
growth factor (NGF) exerts biological activity not only on
the central and peripheral nervous system but also on the
immune system, thereby inﬂuencing allergic diseases and
asthma. NGF is produced by cells of the nervous system,
and also by T and B lymphocytes, which display func-
tional NGF receptors [41, 42]. Bonini et al [43]r e p o r t e d
that NGF circulating levels of NGF are increased in pa-
tients with allergic diseases and asthma. Moreover, NGF
increasesairwayhyperreactivitytohistamineinananimal
model of asthma, while anti-NGF treatment reduces air-
way hyperreactivity in sensitized mouse induced by topi-
cal challenge of ovalbumin.
Geneexpression
There are a number of candidate genes thought to
play a role in the development of asthma. The region of
chromosome 5q31–33 contains several genes that mod-
ulate atopic responses, including IL-4, IL-5, IL-13, and
GM-CSF, as well as the GR and β-AR. Polymorphism
identiﬁed in the IL-13 gene has convincingly been asso-
ciated with a variation in IgE levels and with various fea-
tures of the asthmatic phenotype [44, 45, 46]. The IL-
4 gene is of a great interest because it causes B-cell iso-
type switching from IgM to IgE and stimulates IgE pro-
duction in allergic sensitization. It has been shown that
polymorphism of the IL-4 receptor gene is associated
with atopy and asthma [47]. Moreover, gene-gene inter-
action between IL-4 receptor and IL-13 was associated
with asthma [20]. The gene of the inﬂammatory marker
TNF-α has also been tested as candidate gene leading to
asthma [48]. The recent investigation of Karjalainen et al
[25] showed that also IL-10 gene polymorphism is associ-
ated with eosinophil count and circulating IgE in asthma.
The polymorphism of the β2-AR promotor at posi-
tions 16 (arginine to glycine) and 27 (glutamine to glu-
tamic acid) is known to be functionally relevant and has
been associated with more severe forms of asthma, noc-
turnal asthma, and decreased airway responsiveness in
asthmatic subjects [49].
It has been shown that corticosteroid-resistant
bronchial asthma is associated with increased c-fos ex-
pression in T lymphocytes [50]. Glucocorticoids (GCs)
are involved in the regulation of numerous physio-
logical processes and, as drugs, represent the corner-
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anti-inﬂammatory eﬀects are mediated by the GR-α
which represses expression of various genes encoding in-
ﬂammatorymediators[51].Alternativesplicingofthehu-
man GR gene produces a splice variant, GR-β, termed the
silent receptor. Increased expression of GR-β is found in
GC insensitive patients with asthma [52]. It seems that
overexpression of GR-β may play a role in GC-resistant
asthmatics, whereas in GCs-dependent asthmatics, a pre-
dominant GR-α expression was found. Suppression of
the expression IL-5 and GM-CSF genes by GCs has been
shown in asthmatics recovering from acute exacerbation
of disease [23].
CTLA-4 is a second costimulatory molecule that is ex-
pressed only on activated T cells. It is considered to be
important in the development of many of the immuno-
logical and physiological features of asthma [53]. Poly-
morphisms of the CTLA-4 gene have eﬀects on immune
response in asthma and may serve as a clinically useful
marker of severe asthma [53].
Microarray technology oﬀers the new opportunity
to gain insight into global gene-expression proﬁles in
asthma, allowing the identiﬁcation of novel asthma-
associated and inﬂammatory genes.
Diﬀerentially expressed genes in a monkey model of
allergic asthma showed that of the approximately 40000
cDNAs represented on the microarray, expression lev-
els of 169 changed by more than 2.5-fold in at least
one of the pairwise probe comparisons; these cDNA en-
coded 149 genes, of which 52 were novel and 97 were
known genes for which a role in asthma pathogenesis had
been implicated before, such as chemokines and other
inﬂammation-associated genes, matrix proteins, and ma-
trix metalloproteases,involved in airwayremodeling [54].
Gene expression in a mice model of asthma revealed
among the hundreds of diﬀerentially expressed genes the
unexpected observation of the increased expression of
arginase [55].
Gene-expression proﬁling airway inﬂammation in
mice showed that of the 1176 genes on the array, the ex-
pression patterns of 280 genes were consistently altered.
Of these genes, the steady-state levels of 93 genes were up-
regulated and 29 were downregulated [56].
The eﬀect of inhaled corticosteroid therapy on gene
expression was followed using bronchial mucosa biopsies
from healthy controls and subjects with allergic asthma,
it appeared that corticoid therapy normalizes partly or
completely the expression of 26 of the 79 genes of known
function identiﬁed as diﬀerentially expressed in asthmat-
ics [57].
To conclude, there are several abnormalities of func-
tion and metabolism of lymphocytes in which an altered
gene expression plays a main role. In particular, diﬀer-
ently expressed genes involved in inﬂammation remodel-
ing and epithelium activation, genes encoding cytokines,
transcription factors, costimulatory molecules, lympho-
cytic receptors, and other genes with unknown functions
were detected. But, till present, there are no reports of




RA is a chronic, autoimmune inﬂammatory disease
of the synovium with progressive destruction of aﬀected
joints. The Th1 cells are thought to contribute to the in-
ﬂammation by inducing high levels of the proinﬂamma-
tory cytokines TNFα, IL-1, IL-6, and IL-17 in the syn-
ovium [58], which leads to cartilage destruction and bone
erosions [59]. IL-6 prompts B cells to diﬀerentiate and
mature into antibody-secreting cells. Increased levels of
IL-6 correlate with increased levels of rheumatoid factor.
Moreover, IL-6 enhances bone resorption and may play a
roleintheperiarticularosteoporosischaracteristicofearly
RA [60]. Also it stimulates the production of C-reactive
protein in RA, nonspeciﬁc indicator of disease activity
[60].IL-4mRNAisalmostabsentinRAsynoviumandIL-
4-producing Th2 clones can rarely be detected [61]. IL-2
isthoughttoplayanimportantroleinthepathogenesisof
RA.SerumIL-2levelsandsIL-2Rwereelevatedinpatients
with RA as compared to controls [62, 63].
TNF-α and IL-8 mediate ongoing destruction of car-
tilage, subchondral bone, and other joint-related tissues
[64]. Cytokine IL-18 has been cloned that exhibits power-
ful Th1-promoting activities in synergy with IL-12. IL-18
inducesproductionbyTh1clones[65].IL-18receptorex-
pression was detected on synovial proliferation, upregu-
lates IL-2R expression, and promotes IFN-γ,T N F - α,a n d
GM-CSF lymphocytes and macrophages [66]. Small but
physiologically relevant amounts of IFN-γ and the Th1
cytokine IL-17 are expressed in RA and could contribute
to immune responses, ﬁbroblast activation, and bone de-
struction [67].
B cells have been shown to participate in chronic
rheumatoid synovitis. They undergo antigen-dependent
clonal expansion, aﬃnity maturation, and diﬀerentiation
into plasma cells, and produce rheumatoid factor, a well-
recognized prognostic factor for aggressive RA [68].
Activation of c-fos may be involved in cartilage
metabolism and might play a crucial role in the patho-
genesis of arthritic destruction [69]. TNF-α and IL-6
augmented c-fos gene expression of rheumatoid synovial
cells, but transactivation of c-fos gene became resistant
against cytokine stimulation under prolonged expression
o fc - f o sg e n e[ 70].
GCs are the most powerful anti-inﬂammatory drugs
used in the treatment of RA. In particular, most immuno-
suppressive and anti-inﬂammatory eﬀects are exerted by
an interaction of GRs with AP-1 and NF-kappaB [71].
GCs inhibit also IL-1 and TNF-α forming a cytokine-
HPA axis feedback circuit [71]. The GR number in lym-
phocytes might be helpful to predict which patients with
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and therefore do not or will not require higher doses
[72].
An increased nitric oxide (NO) level as a result of
activity of the enzyme NO synthase has been shown
in the serum and in synovial macrophages of patients
with RA. NO causes chondrocytes apoptosis and plays a
role in various other inﬂammatory and destructive pro-
cesses [73, 74].
An inducible form of this enzyme is present in macro-
phages, polymorphonuclear leukocytes, and NK cells. In
murine models, blockade of NO production prevents and
treats autoimmune disease [75].
Several studies have demonstrated a signiﬁcant rise
and fall in the expression levels of µ-a n dκ-opioid re-
ceptors, respectively, in rat with polyarthritis [76, 77]. In
RA patients, the κ-opioid receptor mRNA was expressed
on T and B cells and NK cells [78]. They also reported
that the levels of expression of κ-opioid receptor mRNA
in lymphocytes were decreased in RA patients in compar-
ison with healthy volunteers; and it was signiﬁcantly re-
lated to the inﬂammatory activity or chronic pain in the
RA patients.
Geneexpression
In RA, inﬂammation of the joint is caused by the
gene products of lymphocytes and other cell types from
the circulating blood presenting in the synovium and
cartilage tissues. To get insights into pathophysiological
pathways, Justen et al [79] used the suppression sub-
tractive hybridization method to identify diﬀerentially
expressed genes in synovial tissue from RA patients.
DNA sequencing identiﬁed 12 gene products including
cytoskeletal γ-actin, ﬁbronectin, superﬁcial zone protein,
IFN-γ inducible genes such as a novel thiol reductase, and
two genes of unknown function (HSIFNIN4, RING3).
Compared to osteoarthritis patients, 9 of the 12 genes
were overexpressed.
Using microarray technology in human RA mono-
cytes, chondrocytes, and synoviocytes, Heller et al [7]
showed that prominent upregulated genes are IL-6, the
MMPs Strom-1, Col-1, Ge1A, HME, and (in certain sam-
ples) PUMP, TIMPs, and the adhesion molecule VCAM.
With the 1046-element array of randomly selectedcDNAs
fromperipheral blood library probes, RAsamples showed
hybridizations to large number of genes. Of these three
genes were upregulated and they are TIMP-1, apoferritin
light chain, and manganese superoxide dismutase (Mn-
SOD), while others were diﬀerentially expressed.
In the rheumatoid nodule there was a prominent ex-
pression of IL-1β,a n dT N F - α together with IL-12, IL-18,
IL-15, and IL-10 represents a cytokine proﬁle similar to
that of the synovial lesion of RA, which is generally ac-
cepted as being due to Th1-mediated inﬂammation [80].
A recent study of the rheumatoid synovium using
cDNA microarray has demonstrated that a total of 121
genes were signiﬁcantly higher expressed in the RA-I tis-
sues, whereas 39 genes were overexpressed in the RA-II
tissues[81].Inthisstudy,anattemptwasmadetosubclas-
sify RA patients based on the global expression of genes in
aﬀected synovial tissue. The RA-II group showed expres-
sion of genes suggestive for ﬁbroblast dediﬀerentiation.
Within the RA-I group, two groups were distinguished;
the RA-Ia group showed predominantly immune-related
geneactivity, whiletheRA-Ibgroup showed anadditional
higher activity of genes indicative of the classical pathway
of complement activation. The diﬀerences in expression
proﬁles provide opportunities to stratify patients based
on molecular criteria that may require diﬀerent treatment
strategies.Thus,alteredexpressionofnumerousgenesina
diﬀerent tissue was observed, including lymphocytes. We
suppose that using a microarray approach in lymphocytes
could be an attractive approach toward our understand-
ing of the molecular mechanisms of pathogenesis of RA
and will allow to identify potential targets for diagnostic
procedures and therapeutic intervention.
SYSTEMIC LUPUS ERYTHEMATOSUS
Molecularmechanisms
SLE involves immune abnormalities in a wide vari-
ety of cell populations including B and T lymphocytes,
monocytes, and NK cells. In murine models of SLE, an
altered production of both Th1 (such as IFN-γ and IL-2)
and Th2 (such as IL-4 and IL-10) cytokines has been re-
ported [82]. The disease activity in animals signiﬁcantly
improved and/or the production of antibodies decreased
by treatment with anti-IFN-γ receptor [83]. A similar ef-
fect was obtained with anti-IL-4 [84] or IL-10 antibodies
[85]. The entire cytokine proﬁle produced by circulating
lymphocytes has as yet not been clearly elucidated in hu-
man SLE. Production of intracellular IL-10 was higher in
B cells (predominantly in the CD5+ c e l ls u b s e t )o fS L E
patients as compared to controls, indicating its implica-
tion in the immune dysregulation in SLE [86]. Serum IL-
10 values seem to reﬂect SLE disease activity and it has
been suggested that overexpression of IL-10 might play
a pathogenic role [87] and that modulation of the level
of IL-10 may be of potential therapeutic beneﬁt [88]. It
has been shown by Sturfelt et al [89] that relative absence
of IL-Ra response appears to be a feature characteristic of
kidney involvement in SLE patients.
Imbalance between Th1 and Th2 cytokines appears
also to be a hallmark for SLE. Patients had increased lev-
els of serum IL-4, IL-10, IL-12, and IL-18. Moreover, IL-
18 has been found to be disease-activity related. A recent
study has demonstrated that IL-12 inhibits in vitro im-
munoglobulin G production in SLE patients and reduces
anti-dsDNA-secreting cells [90].
Several defects of T-cell signal transduction pathways
have been discovered over the last decade [91, 92]. They
include diminished T-cell receptor ζ-chain expression in
T cells in a majority of SLE patients withdefective cAMP-
dependent protein phosphorylation due to deﬁcient ac-
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A (PKA) [93]. Moreover, deﬁcient PKA activity in SLE T
cells may contribute in part to impaired Ca2+ homeostasis
resulting in calcineurin-catalyzed dephosphorylation of
the transcription factor NF-AT. Genes whose tran-
scription is regulated by NF-AT, such as CD154,
Fas ligand, and c-myc, are overexpressed in SLE T cells
[94]. Also Georgescu et al [95] showed increased sponta-
neous apoptosis of lymphocytes that has been linked to
increased IL-10 production, release of FasL, and overex-
pression of the FasR in SLE. Abnormalities of two tran-
scription factors have recently been identiﬁed in SLE T
cells: (1) reduced/absent p65-RelA subunit of NF-kB and
(2) increased phosphorylated cAMP response modulator
(p-CREM) binding to the IL-12 promoter [96].
Changes in the NGF levels were found in plasma of
adult patients with SLE [97]. Already in childhood NGF
levels can be correlated with disease activity [98]. These
resultssuggestthatNGFmayplayaroleinthepathogene-
sis of SLE and that NGF levels may be of prognostic value
in evaluating the course of the disease and outlining the
medication.
Geneexpression
Gene expression in lymphocytes showed high expres-
sion of IL-4, IL-6, IL-10, and TNF-α in SLE patients as
compared to control [99]. The resulting high level of cy-
tokines with strong eﬀe c to np r o l i f e r a t i o na n dd i ﬀerenti-
ation of B lymphocytes could be responsible for charac-
teristic B-cell hyperactivity and autoantibody production
seen in SLE. Results of other investigations [100]d e m o n -
strated impaired production of IL-12 in SLE lymphocytes
and deﬁcient IL-12 p40 gene expression. Downregulation
of IL-12 p40 gene expression appears to be the cause of
IL-12 p70 deﬁciency in SLE. IL-12 and IFN-γ inhibit IL-
10 expression and reduce IL-10-secreting cells. This indi-
cates that correction of the deﬁciency of IL-12 and IFN-γ
in SLE may normalize pathogenically excessive IL-10 and
help remit the disease.
R u se ta l[ 8] using cDNA microarray in PBMCs of
21 SLE patients and 12 controls demonstrated that of
375 potentially relevant genes 50 genes exhibited more
than 2.5-fold diﬀerence in expression level compared to
healthy control and twenty genes were signiﬁcantly diﬀer-
ent. Most of these genes have not previously been asso-
ciated with SLE and belong to a variety of families such
as TNF/death receptor, IL-1 cytokine family, and IL-8 and
its receptors. For ﬁve of the diﬀerentially expressed genes
found in this study, changes at the protein-expression
level have been previously reported in SLE. These inves-
tigators have recently published expression pattern of 375
genes in PBMCs from 12 patients with active and 14 pa-
tients with inactive diseases; 29 genes were found to best
discriminate. Among these genes, 14 were upregulated
and 15 were downregulated in patients with active dis-
eases compared to those with inactive diseases. Most of
these genes have not been previously associated with dis-
ease activity and belong to a variety of families such as ad-
hesion molecules, proteases, TNF superfamily, and neu-
rotrophic factors [101]. Very interesting results that im-
munosuppressive therapy modulates T lymphocyte gene
expression in SLE patient were presented by Pereira et al
[102]. They observed that untreated patients have 38
repressedgenesascomparedtohealthycontrol.Whenun-
treated patients were compared to treated ones, 154 genes
were upregulated.
Serum soluble receptor (srIL2f, p55 srTNFf, p75 srT-
NFf) levels were higher in SLE patients with nephritis be-
fore treatment and decreased signiﬁcantly 6 month after
treatment, suggesting that soluble receptors of cytokines
are sensitive markers of diseases activity [103, 104]. SLE
B cells have bone-resorbing activity which corresponds to
IL-α,a n dI L - α produced by B cells might be one of the
causes of bone destruction in SLE patients which has also
been reported [105].
In T cells from patients with SLE, activity of type 1
protein kinase A isozymes is greatly reduced because of
decreased expression of the α and β regulatory subunits
(RIα and RIβ). Mutations of the RIα subunit were ob-
served in T cells of patients with SLE, caused by over-
expression of an IFN-α-inducible transcript editing gene,
ADAR1 [106].
Gene-expression proﬁling with a microarray using
PBMCs from SLE patients and controls comprised of
monocytes/macrophages, B and T lymphocytes, and NK
cells demonstrated expression of 4566 genes represented
on the chip. This analysis identiﬁed 161 unique genes
that were diﬀerentially expressed by the following crite-
ria: changes in expression of least 1.5-fold, and diﬀer-
ence in expression of at least 100 expression units when
comparing the means of two groups. Most of the genes
that best distinguished SLE from control PBMCs were
more expressed in SLE (124 of 161, 77%). Many SLE pa-
tientswerefoundtooverexpressmRNAforthecellsurface
markers: TNFR6 (Fas/CD95), a death receptor, intercellu-
lar adhesion molecule-1 (CD54), a lymphocyte activation
antigen, and complement receptor. Other notable overex-
pressedgenesincludedthesignalingmoleculesMAP3K-8,
RAB27, and the interleukin-6 signal transducer, and the
transcription factors v-ets 2, and others [107].
Increased IFN-γ, IL-10 and decreased IL-4 mRNA ex-
pression in PMBCs from patients with SLE have been re-
ported [108]. The results of several investigations showed
thatIFN-regulatedgenesareamongthemostsigniﬁcantly
overexpressed in SLE mononuclear cells [109].
The changes in gene expression after IFN treatment
have recently been investigated. This analysis identiﬁed
286 genes that demonstrated > 2-fold change in expres-
sion from baseline, and absolute mean diﬀerence in the
level of expression > 500 units. The induction of many
IFN-regulated genes, such as STAT1, myxovirus resistance
1(Mx-1), and ISGF-3, validated the approach. Linear re-
gression analysis showed that the IFN score was signiﬁ-
cantly correlated with the number of SLE criteria, so an
elevated IFN score is strongly associated with the most2005:6 (2005) Microarray Proﬁling of Lymphocytes in Internal Diseases 323
Table 1. Examples of general gene-expression proﬁles and disease-speciﬁc proﬁles in asthma, RA, and SLE. (∗ nonspeciﬁc gene
expression, ∗∗ disease-speciﬁc gene expression, — no information.)





IL-12 p40 — — ∗∗
TNFα ∗∗ ∗
IFNγ ∗∗ ∗
c-fos ∗∗ ∗∗ —
TNFR6 (Fas/CD95) — — ∗∗
CD54 — — ∗∗
MAP3K-8 — — ∗∗
RAB27 — — ∗∗
RAG genes — — ∗∗
ADAR1 — — ∗∗




β2-AR gene ∗∗ ——
GR-α/β ∗∗ ——
MR2/5 ∗∗ ——
NGF ∗ — ∗
Cytoskeletal γ-actin — ∗∗ —
Fibronectin — ∗∗ —
MMPs Strom — ∗∗ —
Col-1 — ∗∗ —
HME — ∗∗ —
PUMP — ∗∗ —
VCAM — ∗∗ —
severe manifestation of SLE [107]. In addition, enhanced
mutational activity of immunoglobulin genes has been
implicated in the pathogenesis SLE [110, 111]. Although
the causes of autoantibody production have not been
completely delineated, it has been proposed that a failure
of editing or revision of autoreactive B-cell receptors con-
tributes [112]. The rearrangement of immune-receptor
genes depends on recombination activating gene (RAG)
enzymes [113] .Ar e c e n ts t u d yo fG i r s c h i c ke ta l[ 114]
has showed that RAG expression is upregulated in periph-
eral IgD+ and VpreB+ B cells of patients with active SLE.
These cells may contribute to the immunoregulatory ab-
normalities in patients with SLE. Thus, there are several
well-documented disturbances of gene expression in lym-
phocytes in SLE. Therefore, these cells have the potential
for identiﬁcation of genes responsible for development
and progression of SLE, prognosis, and treatment strate-
gies.
Comparisonoftheexpressionproﬁles
In Table 1, we summarize the expression proﬁles of
PMBCs during the diseased state of asthma, RA, and SLE.
It can be concluded that there is a signiﬁcant overlap con-
cerning direct inﬂammatory markers, whereas of the oth-
ers no systematic investigations are known to conclude
disease speciﬁcity. Such data show that inﬂammation-
related gene expression is likely to be of little use for di-
agnostic purposes, but may be well suitable to follow the
time course of the 3 disorders.
Methodologicalconsiderations
Any method of isolation of white blood cells stim-
ulates lymphocytes and mRNA expression. Therefore,
the method of collection lymphocytes should be well
standardized. In addition, a lymphocyte activation pro-
cedure may be considered. Accordingly, the expres-
sion of particular mRNA may thus become increased324 Anatoliy Gladkevich et al 2005:6 (2005)
several-fold allowing precise determination. We have ex-
perience using Ca2+-ionophore to increase the expres-
sion of transduction-associated genes several up to 100-
fold (unpublished data). It is therefore important to
standardize collection of PBMCs carefully, which may
pose a logistic burden in interinstitutional clinical inves-
tigations. In some cases, a speciﬁc activation technique or
circumstances may be necessary to optimize gene expres-
sion. Gene expression requires speciﬁc laboratory facili-
ties, but in essence PBMCs can be recovered at an extra-
laboratory site and shipped afterwards to laboratory facil-
ities for activation and mRNA extraction. In this scenario,
there must be equipment available to isolate vital cells
from blood on location, including a cooled centrifuge.
Then storage and transport of vital cells become manda-
tory.Inthelastdecade,techniqueshavedevelopedtokeep
cells vital forlonger periods (months) by controlledfreez-
ing (eg, −1◦C per min) and then storing them at −80◦C.
Although these logistic problems can be overcome, most
experiments will be designed in such a manner that blood
can be taken at a laboratory facility.
It is here not the place to discuss strong and weak
points of the microarray technique in detail. Excellent re-
views on technical aspects have appeared and sources are
available online at http://www.gene-chips.com/.S ow ea r e
not discussing the variations of the technique itself, but
rather whether some of the shortcomings of the tech-
niques may be avoided or at least the consequences of
them reduced. The basis of the microarray technique is
those cDNA oligonucleotides spotted on the array that
are complementary to the mRNA of the biological sam-
ple. But because of a nonspeciﬁcity of the binding, there
isarelativelylargenoiseandconsequentlyalowsignal-to-
noise ratio. In particular, when the levels of expression of
the mRNA are low, the general background ﬂuorescence
and nonspeciﬁc binding of the labels mRNA’s at the mi-
croarray may overshadow the biologically signiﬁcant sig-
nals. Ampliﬁcation of the mRNA, to reach higher levels
of mRNA, is then considered. Such ampliﬁcation may,
however, not always be linear and may artiﬁcially increase
or decrease the relative expression. Pooling of mRNA ex-
tracts of various blood samples may indeed lead to higher
biological signals, but may also dilute the relevant diﬀer-
ences, unless done carefully. We will propose a procedure
for optimal pooling (see below).
Finally, we would emphasize the potential of the mi-
croarray technique to allow direct comparison of 2 sam-
ples with each other on a single microarray. In that case,
the biomedical samples are stained with diﬀerent ﬂuo-
rescent labels (Cy3 and Cy5), so the ratio of the labels
indicates the relative expression of a gene. In such anal-
ysis, an ideal competition between the diﬀerentially la-
beled mRNA’s is assumed to occur. This may, however,
not be the case, as labeling may inﬂuence binding prop-
erties. Such complication may well be avoided by repeat-
ing the assay, but with changing the labeling. If its results
are consistent, it is obvious that labeling did not inﬂu-
ence the proﬁles. Another concern may be the technique
of averaging the signal. In most procedures, the average
ﬂuorescence of the chip is taken as an indication of the
meanbackground. Suchsignal may, however, be unevenly
distributed over the array and in some cases mean back-
ground of an area surrounding the genes of interest is
taken, which may comprise less than 10% of the all de-
tected gene products.
Dedicatedclinicaldesigns
Peripheral white blood cells (and lymphocytes) are
easy to obtain and express a substantial part of the human
genome. Here we will discuss some of the potentials and
also pitfalls of the current use of microarrays in clinical
studies. It may be emphasized here again that mRNA dif-
fers from gene analysis as it shows state-dependent varia-
tions, for example, it can be used to assess diﬀerences of
gene expression in the diseased and the recovered state
of the same subject. In the currently published studies,
this unique possibility has not well been exploited. State-
of-the-art microarrays allow detecting the whole genome
(30000 genes) and may easily lead to several thousands of
false positives that are changes seen in cases as compared
to the reference samples. In the case with largely diﬀer-
ent expression, such as in tumor cells, comparison with
nonproliferating cell may suﬃce to discern diﬀerences in
expression. In the here considered use of microarrays in
clinical studies, a far more sophisticated approach is re-
quired to obtain maximal beneﬁt of the array technology.
Another relevant question is whether diﬀerential ex-
pressions should be studied in pairwise or against a refer-
ence sample (or standard). As described below, we pre-
fer to compare the most relevant samples directly, thus
avoiding the use of a reference mixture or sample. In cur-
rentmicroarrays,therelativediﬀerencesinasinglemicro-
array can be shown directly, for example, as one sample is
tagged with green ﬂuorescence and the other (eg, control)
is provided with a red ﬂuorescentlabel. It should be noted
here that the eﬃcacy of the labeling may diﬀer, so that
thereisno guaranteed linearity between thegreenand red
labels.Moreover,eachlabelingisnotalwayslinearandthe
linear range of Cy3 and Cy5 may diﬀer. Current practice
is to label the mRNA extracts to be compared on a single
array in diﬀerent proportions and with alternating label.
Increase of the amount of mRNA increases the signal-
to-noise ratio of the array. Moreover, genes that are very
well expressed give—obviously—a better signal-to-noise
ratio as well. The relative diﬀerences in expression may
well diﬀer more than 1000000 for the genes. Pooling of
samples may well increase the sensitivity of the measure-
ment,butstillcombining10bloodsamplestheexpression
levelmaystillremainlowandmarginal.Poolinghas,how-
ever, in addition to the possible increased signal-to-noise
ratio also the advantage that it may eliminate some of the
biological variance. For instance, consider a noise of 100
and a net biologically relevant signal of 30, so to conclude
to a signiﬁcant diﬀerence one must distinguish 100 from2005:6 (2005) Microarray Proﬁling of Lymphocytes in Internal Diseases 325
130,whichfallsbelowthecurrenttechnicalpossibilities.If
however one pools 5 samples, then the diﬀerence between
(relevant) signal and noise is now 100 and 250, which is
well detectable. But also in an attempt to detect the diﬀer-
ences between state 1 and state 2 of a subject, pooling of
the extracts obtained at state 1 versus those at state 2 may
well be helpful. If, for example, the relative alterations in
gene expression are variable and small, but the direction
of change is similar, already pools of 5 samples and 10 ar-
rays may well allow the identiﬁcation of a small number
of genes, characteristic for the disease state investigated.
CONCLUSION
In this review, we summarize relevant investigations
of the gene expression in asthma, RA, and SLE, internal
diseases with altered immune response in which lympho-
cytes play a central role. In our opinion, microarray stud-
ies in human lymphocytes would allow us to monitor al-
teration in gene expression relevant to asthma, RA and
SLE and to possibilities of future therapeutically interven-
tion. Further characterization of the gene expression in
lymphocytes using cDNA microarray could help identify
moreprecisepathophysiologicalmechanismsinthesedis-
orders, and could ﬁnd beneﬁcial therapeutic approaches.
This suggestion has recently been supported demonstrat-
ing coordinate overexpression of interferon-α-induced
genes using PMBCs as model in SLE [115]. SLE is char-
acterized by various alterations in gene (and gene prod-
ucts) expression leading to diverse dysfunctions of T cells,
B cells, and NK cells and as result development of clinical
symptoms. Our suggestions have also been supported by
the very recent report of Qing and Putterman [116]f r o m
the 4th International Congress of Autoimmunity.
Most of the genes involved in the pathogenesis of
these diseases are belonging to sets of signal trans-
duction molecules, inﬂammation-related cytokines (and
chemokines), apoptosis-inducing molecules, cell-cycle
proteins, or transcription factors. Most of these subsets of
genes are now commercially available to be used on vari-
ous microarray systems. The application of these systems
has become more user-friendly and less expensive lately,
and approaches the point to be a common tool available
at most medicine departments. Alizadech et al [117, 118]
have developed a “lymphochip,” which is a microarray
of merely 10000 individual human cDNA, representing
genesofknownandunknownfunctionexpressedonlym-
phocytes.
Such microarray technique gives the clues for identi-
fying a novel responsible genes which underlie the pro-
cess of the disease, and also could help identify appro-
priate targets for therapeutic intervention. Beside this,
the microarrays using a “lymphochip” could be poten-
tial tools for investigating the mechanism of drug action.
The use of the microarrays does not allow only compari-
son of the expression proﬁle in diﬀerent subjects (for in-
tersubject designs), but also in individuals before, during,
and after the disease (for intrasubjects designs). Lympho-
cytes are an easily accessible model to be investigated with
microarray techniques. This approach is minimally inva-
sive, brings us valuable information at the cellular and
molecular level of the disease, and can be universally ap-
plied in clinical medicine. There are, however, many po-
tential pitfalls in the use of microarrays that result in false
leads and erroneous conclusion [119] .I no r d e rt oc o n -
trol the many sources of variation and the many oppor-
tunities for misanalysis, DNA microarray studies require
careful planning, experimental design, statistical analysis,
and interpretation. Diﬀerent studies have diﬀerent objec-
tives, and important aspects of design and analysis strat-
egy diﬀer for diﬀerent types of studies. Studies of dis-
ease with cDNA microarray technology can be split into
two main categories with interrelated goals: identiﬁca-
tion of key molecular changes in diseases and identiﬁca-
tion of biomarkers or molecular ﬁngerprints that will aid
in patient diagnosis and classiﬁcation. Studies that iden-
tify molecular changes in disease will advance our under-
standing of disease pathophysiology, whereas studies that
identify biomarkers will improve diagnostic accuracy and
targeting of speciﬁc therapeutic interventions [120]. We
therefore suggest that exploring of the cDNA microarray
gene expression in blood lymphocytes could be an advan-
tageous and powerful tool for research, diagnostic, and
treatment purposes in internal medicine.
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